Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11703085 | 0.87 | ADH1B (0.31) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL6046773 | 0.84 | OPRM1 (0.39) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL12786311 | 0.83 | ADH1B (0.32) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL1142799 | 0.82 | TSHR (0.38) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL1142707 | 0.82 | TSHR (0.38) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL1142759 | 0.82 | TSHR (0.38) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL1142452 | 0.82 | TSHR (0.38) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL19356850 | 0.78 | TSHR (0.39) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL1142556 | 0.77 | DNM1 (0.38) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1142866 | 0.77 | DNM1 (0.38) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263774-B2 | Quinoline-oxazoline compounds and their use in oxidation synthesis | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263774-B2 | Quinoline-oxazoline compounds and their use in oxidation synthesis | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263774-B2 | Quinoline-oxazoline compounds and their use in oxidation synthesis | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054176-A1 | QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS | XDH, OXA1L, AOX1 | OPRM1 125/4885ADH1B 322/4885ADH1C 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.